APAP toxicity, whether resulting from a single overdose or repeated supratherapeutic ingestion, progresses through four phases: preclinical toxic effects (phase one), hepatic injury (phase two), hepatic failure (phase three), and recovery (phase four)
Recognizing that there will be broader adoption of GLP-1 medications for weight loss as the drugs become more affordable and convenient, Ramon Laguarta, chief executive officer of PepsiCo, Inc., said he is optimistic about how the company can play in that new reality We have been working on this for some time, he said during a Feb
The 2025 FTC guidance signaled a zero-tolerance posture, and proposed legislation would make product hopping presumptively anticompetitive
This opens the prospect of integrative approaches combining pharmacotherapy with microbiome modulation and establishes a foundation for novel strategies, such as genetically engineered probiotics capable of locally producing GLP-1 in the intestine